"Overview of Heartburn
The esophagus is a tube that connects the mouth to the stomach. It is made of muscles that work to push food toward the stomach in rhythmic waves. Once in the stomach, food is prevented from refluxing (moving b"...
Dexilant and Dexilant SoluTabs
The following serious adverse reactions are described below and elsewhere in labeling:
- Acute Interstitial Nephritis [see WARNINGS AND PRECAUTIONS]
- Cyanocobalamin (Vitamin B-12) Deficiency [see WARNINGS AND PRECAUTIONS]
- Clostridium Difficile Associated Diarrhea [see WARNINGS AND PRECAUTIONS]
- Bone Fracture [see WARNINGS AND PRECAUTIONS]
- Hypomagnesemia [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of DEXILANT capsules was evaluated in 4548 patients in controlled and uncontrolled clinical studies, including 863 patients treated for at least six months and 203 patients treated for one year. Patients ranged in age from 18 to 90 years (median age 48 years), with 54% female, 85% Caucasian, 8% Black, 4% Asian, and 3% other races. Six randomized controlled clinical trials were conducted for the treatment of EE, maintenance of healed EE, and symptomatic GERD, which included 896 patients on placebo, 455 patients on DEXILANT 30 mg capsules, 2218 patients on DEXILANT 60 mg capsules, and 1363 patients on lansoprazole 30 mg once daily.
Common Adverse Reactions
The most common adverse reactions ( ≥ 2%) that occurred at a higher incidence for DEXILANT capsules than placebo in the controlled studies are presented in Table 3.
Table 3: Common Adverse Reactions in Controlled
|DEXILANT 30 mg capsules
|DEXILANT 60 mg capsules
|DEXILANT capsules Total
|Lansoprazole 30 mg
|Upper Respiratory Tract Infection||0.8||2.9||1.7||1.9||0.8|
Adverse Reactions Resulting In Discontinuation
In controlled clinical studies, the most common adverse reaction leading to discontinuation from DEXILANT therapy was diarrhea (0.7%).
Less Common Adverse Reactions
Other adverse reactions that were reported in controlled studies at an incidence of less than 2% are listed below by body system:
Endocrine Disorders: goiter
Eye Disorders: eye irritation, eye swelling
Gastrointestinal Disorders: abdominal discomfort, abdominal tenderness, abnormal feces, anal discomfort, Barrett's esophagus, bezoar, bowel sounds abnormal, breath odor, colitis microscopic, colonic polyp, constipation, dry mouth, duodenitis, dyspepsia, dysphagia, enteritis, eructation, esophagitis, gastric polyp, gastritis, gastroenteritis, gastrointestinal disorders, gastrointestinal hypermotility disorders, GERD, GI ulcers and perforation, hematemesis, hematochezia, hemorrhoids, impaired gastric emptying, irritable bowel syndrome, mucus stools, oral mucosal blistering, painful defecation, proctitis, paresthesia oral, rectal hemorrhage, retching
Immune System Disorders: hypersensitivity
Laboratory Investigations: ALP increased, ALT increased, AST increased, bilirubin decreased/increased, blood creatinine increased, blood gastrin increased, blood glucose increased, blood potassium increased, liver function test abnormal, platelet count decreased, total protein increased, weight increase
Additional adverse reactions that were reported in a long-term uncontrolled study and were considered related to DEXILANT by the treating physician included: anaphylaxis, auditory hallucination, B-cell lymphoma, bursitis, central obesity, cholecystitis acute, dehydration, diabetes mellitus, dysphonia, epistaxis, folliculitis, gout, herpes zoster, hyperlipidemia, hypothyroidism, increased neutrophils, MCHC decrease, neutropenia, rectal tenesmus, restless legs syndrome, somnolence, tonsillitis.
See the full prescribing information for lansoprazole for other adverse reactions not observed with DEXILANT.
The following adverse reactions have been identified during post-approval of DEXILANT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Ear and Labyrinth Disorders: deafness
Eye Disorders: blurred vision
Gastrointestinal Disorders: oral edema, pancreatitis
General Disorders and Administration Site Conditions: facial edema
Hepatobiliary Disorders: drug-induced hepatitis
Infections and Infestations: Clostridium Difficile associated diarrhea
Metabolism and Nutrition Disorders: hypomagnesemia, hyponatremia
Musculoskeletal System Disorders: bone fracture
Renal and Urinary Disorders: acute renal failure
Skin and Subcutaneous Tissue Disorders: generalized rash, leukocytoclastic vasculitis
Read the Dexilant and Dexilant SoluTabs (dexlansoprazole capsules and tablets) Side Effects Center for a complete guide to possible side effects
Tables 4 and 5 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with DEXILANT and instructions for preventing or managing them.
Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.
Table 4: Clinically Relevant Interactions Affecting
Drugs Co-Administered with DEXILANT and Interactions with Diagnostics
|Clinical Impact:||The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.
|Intervention:||Rilpivirine-containing products: Concomitant use with DEXILANT is contraindicated [see CONTRAINDICATIONS]. See prescribing information.
Atazanavir: See prescribing information for atazanavir for dosing information.
Nelfinavir: Avoid concomitant use with DEXILANT. See prescribing information for nelfinavir.
Saquinavir: See the prescribing information for saquinavir and monitor for potential saquinavir toxicities.
Other antiretrovirals: See prescribing information.
|Clinical Impact:||Increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.|
|Intervention:||Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin.|
|Clinical Impact:||Concomitant use of PPIs with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted [see WARNINGS AND PRECAUTIONS].|
|Intervention:||A temporary withdrawal of DEXILANT may be considered in some patients receiving high-dose methotrexate.|
|Clinical Impact:||Potential for increased exposure of digoxin.|
|Intervention:||Monitor digoxin concentrations. Dose adjustment of digoxin may be needed to maintain therapeutic drug concentrations. See prescribing information for digoxin.|
|Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenoloate mofetil, ketoconazole/itraconazole)|
|Clinical Impact:||Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.|
|Intervention:||Mycophenolate mofetil (MMF): Co-administration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving DEXILANT and MMF. Use DEXILANT with caution in transplant patients receiving MMF.
See the prescribing information for other drugs dependent on gastric pH for absorption.
|Clinical Impact:||Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.|
|Intervention:||Monitor tacrolimus whole blood trough concentrations. Dose adjustment of tacrolimus may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus.|
|Interactions with Investigations of Neuroendocrine Tumors|
|Clinical Impact:||CgA levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors [see WARNINGS AND PRECAUTIONS, CLINICAL PHARMACOLOGY].|
|Intervention:||Temporarily stop DEXILANT treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.|
|Interaction with Secretin Stimulation Test|
|Clinical Impact:||Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma.|
|Intervention:||Temporarily stop DEXILANT treatment at least 30 days before assessing to allow gastrin levels to return to baseline [see CLINICAL PHARMACOLOGY].|
|False Positive Urine Tests for THC|
|Clinical Impact:||There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs.|
|Intervention:||An alternative confirmatory method should be considered to verify positive results.|
Table 5: Clinically Relevant Interactions Affecting
DEXILANT When Co-Administered with Other Drugs
|CYP2C19 or CYP3A4 Inducers|
|Clinical Impact:||Decreased exposure of dexlansoprazole when used concomitantly with strong inducers [see CLINICAL PHARMACOLOGY].|
|Intervention:||St. John’s Wort, rifampin: Avoid concomitant use with DEXILANT. Ritonavir-containing products: See prescribing information.|
|CYP2C19 or CYP3A4 Inhibitors|
|Clinical Impact:||Increased exposure of dexlansoprazole is expected when used concomitantly with strong inhibitors [see CLINICAL PHARMACOLOGY].|
|Intervention:||Voriconazole: See prescribing information.|
|Alcohol and DEXILANT SoluTab|
|Clinical Impact:||Alcohol may modify the release rate of dexlansoprazole from DEXILANT SoluTab, possibly leading to decreased efficacy.|
|Intervention:||Avoid alcoholic beverages when taking DEXILANT SoluTab [see DOSAGE AND ADMINISTRATION].|
Read the Dexilant and Dexilant SoluTabs Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 4/7/2016
Additional Dexilant and Dexilant SoluTabs Information
- Dexilant and Dexilant SoluTabs Drug Interactions Center: dexlansoprazole oral
- Dexilant and Dexilant SoluTabs Side Effects Center
- Dexilant and Dexilant SoluTabs in detail including Side Effects and Drug Images
- Dexilant and Dexilant SoluTabs Overview including Precautions
- Dexilant and Dexilant SoluTabs FDA Approved Prescribing Information including Dosage
Dexilant - User Reviews
Dexilant User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.